The 2026 Revision of China’s Good Clinical Practice Standard: A Once-In-A-Generation Paradigm Shift

Xiangxiang Ma, Partner at Anjie Broad LLP, analyzes a newly-released standard which forms a key part of China’s framework regulating clinical trials

By Xiangxiang Ma

Summary

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

Access to 3000+ essential documents, including key PRC laws translated into English
Newsletters with business-critical and sector-specific updates
Premium mobile access with timely analysis on China’s fast-changing market

Already a Subscriber? Log In Here

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)